Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Summary

The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.

Timeline

Start

2017-07-17

Primary completion

2017-12-06

Completion

2017-12-06

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to terminate the study”

Drugs

Indications